Aktienanalyse wird geladen …
CRL · NYSE · Research & Development · USA
294,37 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4,02 Mrd. | -144,34 Mio. | -2,91 $ | 49,56 Mio. | 0,2 Mio · 0,5 % | — | 33 % | -3,6 % | 10,46 $ | 1,43 $ | — |
| 2024 | 4,05 Mrd. | 22,2 Mio. | 0,20 $ | — | 0,2 Mio | — | 32,9 % | 0,6 % | — | — | — |
| 2023 | 4,13 Mrd. | 474,62 Mio. | 9,22 $ | 51,45 Mio. | 0,2 Mio · 0,5 % | 0,1 Mio · 0,2 % | 36,4 % | 11,5 % | 7,10 $ | 1,40 $ | — |
| 2022 | 3,98 Mrd. | 486,23 Mio. | 9,48 $ | 51,3 Mio. | 0,3 Mio · 0,5 % | 0,4 Mio · 0,7 % | 36,8 % | 12,2 % | 5,75 $ | 1,44 $ | — |
| 2021 | 3,54 Mrd. | 390,98 Mio. | 7,60 $ | 51,43 Mio. | 0,2 Mio · 0,5 % | — | 37,7 % | 11 % | 10,35 $ | 1,39 $ | — |
| 2020 | 2,92 Mrd. | 364,3 Mio. | 7,20 $ | 50,61 Mio. | 0,2 Mio · 0,4 % | — | 36,7 % | 12,5 % | 7,51 $ | 1,11 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 1 Mrd. | -1,48 Mio. | -0,03 $ | 48,02 Mio. | -0,2 % | 3,09 $ |
| Q1 2026 | 995,83 Mio. | -14,84 Mio. | -0,30 $ | 48,95 Mio. | -1,5 % | -0,30 $ |
| Q4 2025 | 994,23 Mio. | -276,56 Mio. | -5,58 $ | — | -27,8 % | 1,18 $ |
| Q3 2025 | 1 Mrd. | 54,42 Mio. | 1,10 $ | 49,43 Mio. | 5,4 % | 3,61 $ |
| Q2 2025 | 1,03 Mrd. | 52,33 Mio. | 1,06 $ | 49,32 Mio. | 5,1 % | 3,43 $ |
| Q1 2025 | 984,17 Mio. | 25,47 Mio. | 0,50 $ | 50,85 Mio. | 2,6 % | 2,21 $ |
| Q4 2024 | 1 Mrd. | -214,5 Mio. | -4,33 $ | — | -21,4 % | 1,69 $ |
| Q3 2024 | 1,01 Mrd. | 69,66 Mio. | 1,35 $ | 51,58 Mio. | 6,9 % | 4,13 $ |
Why Charles River Laboratories (CRL) Stock Is Up Today
Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec
Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel
Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI
Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages. Charles River Laboratories provides research models, discovery services, non-clinical safety assessment, and manufacturing-related testing solutions that help clients evaluate new therapies and products before clinical use. Its business spans three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company also offers specialized support for biologics, microbial testing, endotoxin testing, and cell-based research, serving customers in life sciences, academia, and government research. Headquartered in Wilmington, Massachusetts, Charles River Laboratories plays a key role in the outsourced research and development ecosystem by supplying the tools, services, and scientific expertise used to advance drug discovery and product safety worldwide.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest CRL und jede andere Aktie unbegrenzt.